I have witnessed the devastating effects of the opioid epidemic and mental health while working in healthcare for over 20 years and while serving my local community as a minister and chaplain. I first learned about the benefits of cannabidiol (CBD) through Qredible’s CEO. Endocannabinoids (lipid-based neurotransmitters) produced in the body bind to specific receptors in the nervous system. CBD affects this receptor activity, which reduces inflammation and chronic pain. This quality makes CBD appealing for those seeking relief from pain and other symptoms without the other severe side effects related to some pharmaceutical drugs. As consumer demand for CBD, hemp, and legalized cannabis escalate, improved regulation of these products would seem prudent, together with clinical trials exploring their therapeutic benefits. Product demand usually moves much faster than the above safety measures. In reality, many CBD products circulating in the market are mislabeled and not tested for impurities, including pesticides, heavy metals, and microbial contamination. Consumer safety is a significant issue in this industry. Qredible is quickly becoming a major disruptive force in solving these challenges.